Subcutaneous tissue disease

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:79382
Who is this for?
Show terms as
19Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Subcutaneous tissue disease (Orphanet code 79382) is a broad classification category within Orphanet that encompasses a heterogeneous group of rare disorders primarily affecting the subcutaneous tissue — the layer of fat and connective tissue located beneath the skin (dermis). This grouping includes various conditions such as panniculitis variants, lipodystrophies, subcutaneous fat necrosis, and other rare disorders that involve inflammation, degeneration, or abnormal development of the subcutaneous fat and connective tissue compartment. Because this is a classification group rather than a single discrete disease entity, the clinical features, inheritance patterns, age of onset, and severity vary widely depending on the specific condition within this category. Affected individuals may experience subcutaneous nodules, skin induration, localized or generalized loss or redistribution of subcutaneous fat, pain, inflammation, or skin changes overlying affected areas. Some conditions within this group may also have systemic manifestations affecting metabolic function, particularly when lipodystrophy or widespread fat tissue abnormalities are present. Treatment approaches are highly dependent on the specific underlying diagnosis and may range from anti-inflammatory medications and immunosuppressive therapies for inflammatory panniculitis subtypes, to metabolic management and leptin replacement therapy for certain lipodystrophies. Patients suspected of having a rare subcutaneous tissue disorder should be evaluated by specialists in dermatology, endocrinology, or clinical genetics as appropriate to establish a precise diagnosis and individualized management plan.

Inheritance

Variable

Can be inherited in different ways depending on the underlying gene

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Apr 2026A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer

TerSera Therapeutics LLC — PHASE1

TrialNOT YET RECRUITING
Mar 2026NIS to Examine Disease Activity in SLE Patients Treated With Subcutaneous Anifrolumab in Routine Care

AstraZeneca

TrialNOT YET RECRUITING
Mar 2026A Phase I Study of Single Subcutaneous Dose of SHR-1894 in Healthy Subjects

Suzhou Suncadia Biopharmaceuticals Co., Ltd. — PHASE1

TrialRECRUITING
Feb 2026A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.

Eli Lilly and Company — PHASE1

TrialRECRUITING
Feb 2026Upper Body Subcutaneous Exosome Release in Response to a Meal in Obesity

Mayo Clinic — NA

TrialNOT YET RECRUITING
Dec 2025A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated, HER2+, eBC

Zhimin Shao — PHASE2

TrialNOT YET RECRUITING
Nov 2025A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis

MoonLake Immunotherapeutics AG — PHASE3

TrialENROLLING BY INVITATION
Oct 2025Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and Women

BrightGene Bio-Medical Technology Co., Ltd. — PHASE1

TrialRECRUITING
Aug 2025A Trial of SHR-1139 in Healthy Volunteers

Atridia Pty Ltd. — PHASE1

TrialACTIVE NOT RECRUITING
Aug 2025Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University — NA

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Subcutaneous tissue disease.

View clinical trials →

No actively recruiting trials found for Subcutaneous tissue disease at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Subcutaneous tissue disease community →

Specialists

19 foundView all specialists →
MS
Mikhail Samsonov
Specialist
PI on 17 active trials
GM
Gary Weil, MD
BELLEVUE, WA
Specialist
PI on 5 active trials1 Subcutaneous tissue disease publication
PP
Peter Fischer, PhD
Specialist
PI on 1 active trial
PP
Patrick Kpanyen, PhD
Specialist
PI on 1 active trial
JM
Joseph Elassal, MD, MBA
STAMFORD, CT
Specialist
PI on 1 active trial
AM
Alan Krasner, MD
NEW LONDON, CT
Specialist
PI on 1 active trial1 Subcutaneous tissue disease publication
LM
Linda Morrow, MD
Specialist
PI on 1 active trial1 Subcutaneous tissue disease publication
SM
Steven De Bruyn, MD
Specialist
PI on 1 active trial
TM
Thomas R. Pieber, MD
Specialist
PI on 3 active trials
MM
Michael Pulia, MD, MS
MADISON, WI
Specialist
PI on 1 active trial
JD
James Gibney, Dr
Specialist
PI on 3 active trials
YM
YUSUF MADENDAG
Specialist
PI on 1 active trial1 Subcutaneous tissue disease publication
LP
Lars-Peter Kamolz, MD Prof
Specialist
PI on 1 active trial
MM
Michael P. Heffernan, MD
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Subcutaneous tissue disease.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Subcutaneous tissue diseaseForum →

No community posts yet. Be the first to share your experience with Subcutaneous tissue disease.

Start the conversation →

Latest news about Subcutaneous tissue disease

Disease timeline:

New recruiting trial: An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)

A new clinical trial is recruiting patients for Subcutaneous tissue disease

New recruiting trial: Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)

A new clinical trial is recruiting patients for Subcutaneous tissue disease

New recruiting trial: Effectiveness of a Zinc Oxide Adhesive Securement Device in the Fixation of Midline and Peripherally Inserted Central Catheters in Hospitalized Adult Patients

A new clinical trial is recruiting patients for Subcutaneous tissue disease

New recruiting trial: Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

A new clinical trial is recruiting patients for Subcutaneous tissue disease

New recruiting trial: A Phase I Study of Single Subcutaneous Dose of SHR-1894 in Healthy Subjects

A new clinical trial is recruiting patients for Subcutaneous tissue disease

New recruiting trial: Radiomics of Intra-abdominal and Subcutaneous Adipose Tissue Predict the Efficacy of Bariatric Surgery (RISABS)

A new clinical trial is recruiting patients for Subcutaneous tissue disease

New recruiting trial: An Open-label, Time-lagged, Dose-escalation Study to Evalaute the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.

A new clinical trial is recruiting patients for Subcutaneous tissue disease

New recruiting trial: A RWS of SC MTX in Chinese RA Patients

A new clinical trial is recruiting patients for Subcutaneous tissue disease

New recruiting trial: Efficacy of Neoadjuvant Subcutaneous Trastuzumab-Pertuzumab in Algerian Women With Locally Advanced HER2 Positive Breast Cancer

A new clinical trial is recruiting patients for Subcutaneous tissue disease

New recruiting trial: A Phase I Study to Assess LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus

A new clinical trial is recruiting patients for Subcutaneous tissue disease

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Subcutaneous tissue disease

What is Subcutaneous tissue disease?

Subcutaneous tissue disease (Orphanet code 79382) is a broad classification category within Orphanet that encompasses a heterogeneous group of rare disorders primarily affecting the subcutaneous tissue — the layer of fat and connective tissue located beneath the skin (dermis). This grouping includes various conditions such as panniculitis variants, lipodystrophies, subcutaneous fat necrosis, and other rare disorders that involve inflammation, degeneration, or abnormal development of the subcutaneous fat and connective tissue compartment. Because this is a classification group rather than a si

Which specialists treat Subcutaneous tissue disease?

19 specialists and care centers treating Subcutaneous tissue disease are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.